PRL and neoplasm: In a recent study of women with metastatic breast cancer, however, a significant increase in the objective tumour response rate was seen when the dopamine agonist cabergoline was added to docetaxel versus treatment with docetaxel alone (31/34 versus 13/36, P < 0.05), suggesting that endocrine prolactin protects against chemotherapy-induced cell death [12].